Eliquis
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
NonValvular Atrial Fibrillation
Conditions
NonValvular Atrial Fibrillation
Trial Timeline
Sep 1, 2013 → Aug 31, 2016
NCT ID
NCT02007655About Eliquis
Eliquis is a pre-clinical stage product being developed by Pfizer for NonValvular Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT02007655. Target conditions include NonValvular Atrial Fibrillation.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02007655 | Pre-clinical | Completed |
Competing Products
6 competing products in NonValvular Atrial Fibrillation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0837 + Vitamin-K antagonist at INR 2-3 + AZD0837 | AstraZeneca | Phase 2 | 52 |
| AZD0837 + VKA INR 2-3 | AstraZeneca | Phase 2 | 52 |
| Certoparin | Novartis | Phase 3 | 77 |
| Apixaban | Bristol Myers Squibb | Pre-clinical | 22 |
| Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA) | Bayer | Pre-clinical | 20 |
| Rivaroxaban 20 MG + Warfarin | Bayer | Approved | 82 |